Pharmazz, Inc. is an emerging pharmaceutical company worldwide that operates on a global scale. The company's primary objective is to actively seek out, acquire, develop, and commercialize innovative pharmaceutical products that are intended for use in hospital and critical care settings. Pharmazz Inc. achievements in the Indian market and their potential for future impact are significant. Their focus on critical care medicine holds promise for improving patient outcomes around the world.
Pharmazz Inc. was established in 2010 in Illinois, USA. Pharmazz, Inc. founded its subsidiary in India as Pharmazz India Private Limited and in UK as Pharmazz UK Limited. Anil Gulati is the current CEO of the company.
In 2011, the company entered into licencing agreements with Midwestern University, and in 2014, it struck agreements with the Board of Trustees of the University of Illinois.
Pharmazz has acquired the exclusive global rights to a number of compounds recommended for patients in critical condition from Midwestern University, located in Downers Grove, USA. The business has a solid pipeline of patents in various phases of clinical development and a strong patent position. In 2020, Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India.
In March 2024, Pharmazz Inc. and Dr. Reddy's Laboratories signed a licensing agreement to bring life-saving Centhaquine now marketed as Lyfaquin, to India. Dr. Reddy's will distribute the medicine under the Lyfaquin brand. Additionally, Lyfaquin's Nepali marketing rights have been granted to it. Pharmazz is entitled to royalties and upfront payments.
Products
Pharmazz boasts two key products:
Lyfaquin® (Centhaquine)
The clinical development of centhaquine for hypovolemic shock began in India. clearance for phase I clinical trial was acquired in September 2014, followed by clearance for phase II in December 2016, and approval for phase III in December 2018. The market received authorization in May 2020, and the launch of Lyfaquin® took place in November of the same year.
Lyfaquin is approved for marketing in India, this drug targets hypovolemic shock, a condition where the body lacks sufficient fluids.
Tyvalzi (Sovateltide): This first-in-class drug is for ischemic stroke and has received marketing authorization in India as well. It's currently undergoing Phase III trials for approval in the US. In addition to these, Pharmazz has a pre-clinical program targeting other critical care needs.
Sovateltide in Alzheimer’s Disease
The clinical development of sovateltide commenced in India with a phase I study in July 2016. clearance for a phase II trial in India, specifically for cerebral ischemic stroke, was acquired in August 2017. Subsequently, clearance for a phase III trial was granted in July 2019. Approval for phase II trials of sovateltide in Alzheimer's disease was granted in August 2017, followed by approval for Acute Spinal Cord Injury trials in October 2018.
Licensing and Partnerships
Pharmazz recognizes the value of collaboration. They have a licensing agreement with Sun Pharmaceutical Industries Limited to commercialize Tyvalzi in India. This deal highlights Pharmazz's innovative approach and Sun Pharma's established market presence.
Future Outlook
Pharmazz Inc. is a name to watch in the critical care arena. With a strong pipeline, strategic partnerships, and a focus on unmet medical needs, they are poised to make a significant impact on patient lives. Their journey from developing drugs to achieving marketing authorization in India demonstrates their dedication to bringing relief to critically ill patients.
